Related Experiment Videos
[The predictor for platelet recovery after PBSCT].
1Department of Hematology, Nanfang Hospital, Guangzhou 510515.
Zhonghua Xue Ye Xue Za Zhi = Zhonghua Xueyexue Zazhi
|February 24, 2001
Summary
Predicting platelet recovery after stem cell transplants is crucial. The study found that counting CD34+/CD41a+ cells and colony-forming unit-megakaryocytes (CFU-MK) in grafts helps predict recovery, with CD34+/CD41a+ cells being a more convenient marker.
Area of Science:
- Hematology
- Stem Cell Transplantation
- Cell Biology
Context:
- Peripheral blood stem cell transplantation (PBSCT) is a critical procedure for patients with hematological malignancies and solid tumors.
- Accurate prediction of platelet recovery post-PBSCT is essential for optimizing patient management and outcomes.
- Current predictors may lack the desired accuracy, reliability, or convenience for widespread clinical application.
Purpose:
- To identify a more accurate, reliable, and convenient predictor of platelet recovery capacity following PBSCT.
- To evaluate the correlation between specific cell populations in PBSC grafts and the time to platelet recovery.
- To compare the predictive value of CD34+/CD41a+ cells and colony-forming unit-megakaryocytes (CFU-MK) for platelet recovery.
Summary:
- The study measured megakaryocyte progenitor cells in PBSC grafts from 17 patients using clonogenic (CFU-MK) and flow cytometric assays.
- Results indicated that the number of CD34+/CD41a+ cells and CFU-MK in grafts are significantly correlated with the time to platelet recovery.
- CD34+/CD41a+ cells showed a stronger correlation with platelet recovery time compared to total CD34+ cells and were also closely correlated with CFU-MK counts.
Impact:
- The findings suggest that quantifying CD34+/CD41a+ cells in PBSC grafts can serve as a valuable and convenient predictor for platelet recovery post-PBSCT.
- This improved predictive capability can aid clinicians in anticipating and managing post-transplant recovery, potentially leading to better patient care.
- The study highlights CD34+/CD41a+ cell count as a promising, readily accessible marker for clinical use in assessing platelet engraftment potential.